Owen Sharp, of the Prostate Cancer Charity, says the Abirateron drug allows prostate cancer patients to have "a full and active life."
The drug "improves the level of pain the men have...and means they can be full participants with their family and everyday activity at a time when they are coming towards the end of their life," he says.
During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.
This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price, further information on which patients would benefit most and clarification on how many patients could receive the drug.
These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS.